About the Authors
- Andrea Cuconati
-
* E-mail: acuconati.research@hepb.org (AC); Timothy.Block@drexelmed.edu(TB)
Affiliation Institute for Hepatitis and Virus Research, Hepatitis B Foundation, Doylestown, Pennsylvania, United States of America
- Courtney Mills
-
Affiliation Institute for Hepatitis and Virus Research, Hepatitis B Foundation, Doylestown, Pennsylvania, United States of America
- Cally Goddard
-
Affiliation Institute for Hepatitis and Virus Research, Hepatitis B Foundation, Doylestown, Pennsylvania, United States of America
- Xianchao Zhang
-
Affiliation Drexel Institute for Biotechnology and Virology Research, Drexel University College of Medicine, Doylestown, Pennsylvania, United States of America
- Wenquan Yu
-
Affiliations Institute for Hepatitis and Virus Research, Hepatitis B Foundation, Doylestown, Pennsylvania, United States of America, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, People’s Republic of China
- Haitao Guo
-
Affiliation Drexel Institute for Biotechnology and Virology Research, Drexel University College of Medicine, Doylestown, Pennsylvania, United States of America
- Xiaodong Xu
-
Affiliations Institute for Hepatitis and Virus Research, Hepatitis B Foundation, Doylestown, Pennsylvania, United States of America, Enantigen Therapeutics, Incorporated, Doylestown, Pennsylvania, United States of America
- Timothy M. Block
-
* E-mail: acuconati.research@hepb.org (AC); Timothy.Block@drexelmed.edu(TB)
Affiliations Institute for Hepatitis and Virus Research, Hepatitis B Foundation, Doylestown, Pennsylvania, United States of America, Drexel Institute for Biotechnology and Virology Research, Drexel University College of Medicine, Doylestown, Pennsylvania, United States of America
Competing Interests
A. Cuconati and X. Xu are principals in Enantigen Inc., a small company that may license this technology in the future. Institute for Hepatitis and Virus Research has filed an application for a patent on use of HBF-0079 and derivatives (“disubstituted aminothiazoles”) for treatment of cancer and other diseases. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials. None of the authors have any conflicts of interest to report. The authors accept and adhere to all PLOS ONE policies and practices.
Author Contributions
Conceived and designed the experiments: AC TB HG XX. Performed the experiments: AC CM CG XZ WY. Analyzed the data: AC TB HG XX. Contributed reagents/materials/analysis tools: AC TB HG XX WY. Wrote the paper: AC TB CG HG.